Aarti Drugs Ltd

Aarti Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Drugs Ltd

₹ 474 -0.18%
23 May 10:44 a.m.
aartidrugs.com BSE: 524348 NSE: AARTIDRUGS
About

Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]

It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]

Key Points

Market Leadership
The company is a leading global producer of 50+ API molecules across categories like antibiotics, antiprotozoal, anti-inflammatory, anti-diabetic, and anti-fungal. It is the largest manufacturer of Fluoroquinolones, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole worldwide, and among the top producers of Metformin globally. [1] [2]

Website BSE NSE
  • Market Cap ₹ 4,354 Cr.
  • Current Price ₹ 474
  • High / Low ₹ 635 / 312
  • Stock P/E 27.7
  • Book Value ₹ 136
  • Dividend Yield 0.21 %
  • ROCE 13.4 %
  • ROE 13.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 3.49 times its book value
  • The company has delivered a poor sales growth of 5.86% over past five years.
  • Company has a low return on equity of 13.3% over last 3 years.
  • Company might be capitalizing the interest cost
  • Dividend payout has been low at 6.11% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -4.35%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
641 551 625 626 696 592 578 538 560 493 543 515 623
557 496 555 557 608 520 512 478 490 439 484 454 534
Operating Profit 84 55 70 69 89 72 65 60 69 54 60 60 89
OPM % 13% 10% 11% 11% 13% 12% 11% 11% 12% 11% 11% 12% 14%
1 0 0 1 1 1 1 2 1 0 0 11 2
Interest 6 7 8 9 8 8 8 7 8 7 7 8 7
Depreciation 12 12 12 12 12 12 12 12 12 12 12 12 12
Profit before tax 67 36 50 49 69 53 47 43 50 35 41 52 71
Tax % 21% 28% 27% 25% 23% 25% 26% 26% 27% 23% 26% 26% 13%
53 26 37 37 53 40 35 32 36 27 30 39 61
EPS in Rs 5.72 2.85 3.95 3.96 5.74 4.27 3.76 3.44 3.93 2.93 3.31 4.19 6.69
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
972 1,087 1,076 1,089 1,140 1,454 1,635 1,915 2,251 2,498 2,267 2,174
822 915 900 910 955 1,252 1,387 1,511 1,930 2,212 1,998 1,911
Operating Profit 150 172 176 179 185 203 248 404 321 286 269 263
OPM % 15% 16% 16% 16% 16% 14% 15% 21% 14% 11% 12% 12%
1 1 0 4 1 6 9 7 5 2 4 14
Interest 37 42 47 38 36 41 36 26 23 36 33 30
Depreciation 28 31 36 37 38 40 47 48 47 47 48 48
Profit before tax 86 100 93 108 112 128 175 338 256 205 192 199
Tax % 28% 22% 29% 30% 35% 32% 22% 24% 24% 25% 26% 21%
62 78 66 75 73 87 136 258 195 153 142 157
EPS in Rs 6.38 8.01 6.84 7.91 7.78 9.25 14.56 27.65 21.06 16.50 15.43 17.11
Dividend Payout % 26% 41% 25% 3% 3% 3% 3% 9% 5% 6% 6% 6%
Compounded Sales Growth
10 Years: 7%
5 Years: 6%
3 Years: -1%
TTM: -4%
Compounded Profit Growth
10 Years: 7%
5 Years: 4%
3 Years: -7%
TTM: 11%
Stock Price CAGR
10 Years: 11%
5 Years: 17%
3 Years: 4%
1 Year: -3%
Return on Equity
10 Years: 18%
5 Years: 18%
3 Years: 13%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 12 24 24 24 24 24 23 93 93 93 92 91
Reserves 239 279 326 363 410 495 598 766 880 1,022 1,083 1,160
342 435 465 448 517 471 378 336 519 535 475 516
257 228 240 281 366 384 471 442 543 546 522 506
Total Liabilities 850 967 1,055 1,116 1,316 1,373 1,471 1,637 2,035 2,196 2,172 2,273
373 431 463 542 564 586 612 631 649 634 722 761
CWIP 8 13 34 14 28 32 11 16 60 161 222 273
Investments 5 11 11 18 17 19 20 24 28 29 30 42
464 511 547 541 707 736 828 966 1,297 1,372 1,198 1,196
Total Assets 850 967 1,055 1,116 1,316 1,373 1,471 1,637 2,035 2,196 2,172 2,273

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
95 107 125 174 62 147 196 154 40 162 337 220
-105 -102 -87 -96 -71 -59 -29 -69 -125 -131 -187 -135
11 -5 -37 -78 9 -87 -168 -85 84 -31 -149 -85
Net Cash Flow 2 -1 1 -0 -0 1 -1 -0 -1 0 1 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 104 103 109 93 117 110 104 96 115 117 104 118
Inventory Days 71 77 87 101 132 86 107 125 120 102 107 104
Days Payable 84 75 85 91 125 86 110 94 103 89 96 96
Cash Conversion Cycle 91 105 110 103 124 109 101 127 133 130 115 127
Working Capital Days 90 97 108 103 128 108 95 118 132 128 117 125
ROCE % 22% 21% 18% 17% 17% 17% 20% 33% 21% 15% 14% 13%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
59.98% 59.77% 59.66% 59.57% 58.70% 58.57% 57.47% 57.13% 55.67% 55.64% 55.38% 55.48%
2.07% 1.94% 1.90% 1.94% 1.97% 2.33% 2.10% 2.56% 2.95% 2.50% 2.28% 2.25%
2.76% 3.16% 3.90% 4.09% 4.72% 5.32% 5.26% 5.99% 7.35% 7.83% 8.77% 9.70%
35.19% 35.11% 34.53% 34.39% 34.63% 33.78% 35.16% 34.30% 34.01% 34.01% 33.58% 32.57%
No. of Shareholders 1,86,6741,80,3031,73,2831,69,0901,62,4091,67,4461,70,4141,57,5471,50,2181,90,2811,76,0061,69,761

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls